Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse

PURPOSE: Anti-CD19 chimeric antigen receptor T-cell (19CAR-T) immunotherapy has achieved impressive clinical results in adult and pediatric relapsed/refractory (r/r) B-lineage acute lymphoblastic leukemia (B-ALL). However, the application and effect of CAR-T therapy in B-ALL patients with extramedul...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Xinyu, Yang, Xiaomin, Yang, Fan, Wang, Tianyi, Ding, Lixia, Song, Lili, Miao, Yan, Wang, Xiang, Ma, Yani, Luo, Chengjuan, Tang, Jingyan, Gu, Longjun, Chen, Jing, Tang, Yanjing, Lu, Jun, Li, Benshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296935/
https://www.ncbi.nlm.nih.gov/pubmed/34583462
http://dx.doi.org/10.4143/crt.2021.399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296935/
https://www.ncbi.nlm.nih.gov/pubmed/34583462
http://dx.doi.org/10.4143/crt.2021.399

Ejemplares similares